A phase 3 open label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients with metastatic breast cancer who have stable brain metastases and have been
|Effective start/end date||11/1/16 → 11/30/22|
- NEKTAR THERAPEUTICS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.